# HIV Testing, Prevention, Treatment and Medication-Assisted Therapy Achievements for People who Inject Drugs in CDC/PEPFAR-Supported Countries, 2021-2022

Ansley Lyn<sup>1</sup>, Robert Nelson<sup>1</sup>, Mallory Michalak<sup>1</sup>, Hanna Demeke<sup>1</sup>, Gaston Djomand<sup>1</sup>, Beatrice Gichuhi<sup>1</sup>, Ugonna Ijeoma<sup>1</sup>, Wade Ivy, III<sup>1</sup>, Dejana Selenic-Stanacev<sup>1</sup>, Trista Bingham<sup>1</sup>

<sup>1</sup>US Centers for Disease Control and Prevention (CDC), Center for Global Health, Division of Global HIV and TB, Atlanta, GA, USA

### **Background**

- People who inject drugs (PWID) face increased risk for HIV and challenges accessing HIV prevention, testing, and treatment services.
- These challenges often result from stigma, discrimination, and the criminalization of drug use, which limits their access to health services.
- Through the United States (US) President's Emergency Plan for AIDS Relief (PEPFAR), the US Centers for Disease Control and Prevention (CDC) has supported the delivery of HIV testing, prevention, and treatment services to PWID to address their disproportionately high HIV risk.

In fiscal year 2022, CDC-supported partners provided HIV **prevention** outreach for **55%** (214,859) and HIV **testing** for **54%** (191,178) of all **PWID** beneficiaries engaged in 22 PEPFAR countries.



Methadone being prepared for distribution by Ngara Medication Assisted Therapy (MAT) Clinic, an implementing partner of CDC Kenya in Nairobi.

#### **Methods**

Using routinely collected, aggregate-level programmatic data reported to PEPFAR's Monitoring, Evaluation and Reporting (MER) system, we describe the number and percentage of PWID receiving HIV testing, prevention, and treatment services delivered by CDC-funded and supported implementing partners (IPs) between October 2021 and September 2022 (fiscal year 2022) in 22 PEPFAR countries.

#### Results

CDC-supported partners also contributed the following:

- 56% (12,276) of new HIV diagnoses among all PWID
- 53% (16,866) of PrEP initiations for HIV-negative PWID
- 56% (11,322) of HIV-positive PWID linked to antiretroviral therapy (ART)
- 75% (59,946) of total viral load testing among PWID in PEPFAR-supported countries
- 96% of PWID tested for viral load were virally suppressed
- 90% (24,621) of PWID provided medication-assisted therapy (MAT) for at least 6 months

#### **Conclusions**

Despite the persistent structural barriers to access HIV services, CDC and its supported IPs in 22 PEPFAR countries have reached this marginalized population and provided substantial levels of medication-assisted therapy as well as HIV testing, prevention, and treatment services.

| Indicator   | CDC     | Other<br>PEPFAR | Total   | % of Total<br>for CDC |
|---|---------|-----------------|---------|-----------------------|
| Num of PWID reached with HIV prevention interventions (KP_PREV)         | 212,859 | 172,326         | 385,185 | 55%                   |
| Num of PWID on MAT for at least<br>6 months<br>(KP_MAT)                 | 24,721  | 2,841           | 27,562  | 90%                   |
| Num of PWID receiving HIV testing and results (HTS_TST)                 | 191,178 | 163,560         | 354,738 | 54%                   |
| Num of PWID receiving a negative<br>HIV test result<br>(HTS_TST_NEG)    | 178,902 | 153,900         | 332,802 | 54%                   |
| Num of PWID newly enrolled on PrEP (PrEP_NEW)                           | 16,866  | 15,228          | 32,094  | 53%                   |
| Num of PWID receiving a positive<br>HIV test result<br>(HTS_TST_POS)    | 12,276  | 9,660           | 21,936  | 56%                   |
| Num of PWID newly enrolled on ART (TX_NEW)                              | 11,320  | 8,788           | 20,108  | 56%                   |
| Num of PWID currently on ART (TX_CURR)                                  | 75,415  | 32449           | 107,864 | 70%                   |
| Num of PWID on ART with documented viral load test result (TX_PVLS [D]) | 59,946  | 19,876          | 79,822  | 75%                   |
| Num of PWID on ART with suppressed viral load (TX_PVLS [N])             | 57,403  | 19,277          | 76,680  | 75%                   |

### Acknowledgements

We acknowledge the important contributions of PEPFAR staff, facilities, and beneficiaries globally, who are vital to the success of programming for PWID.

## **Contact Information**Ansley Lyn



+1 770 488 7144

This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.